Dexfenfluramine: An updated review of its therapeutic use in the management of obesity

Drugs

Volumn 52, Issue 5, 1996, Pages 696-724

  Davis, Rick ^a   Faulds, Diana ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; DEXFENFLURAMINE; EPHEDRINE; FLUOXETINE; LIPID; SEROTONIN; SEROTONIN RECEPTOR; SIBUTRAMINE;

APPETITE; BODY WEIGHT; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DIET THERAPY; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSOMNIA; LIPID BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; POLYURIA; PRESYNAPTIC NERVE; REVIEW; RISK FACTOR; SEROTONIN RELEASE; SEROTONIN UPTAKE; SOMNOLENCE; SYNAPSE; TREMOR; WEIGHT REDUCTION; XEROSTOMIA;

ANIMALIA;

EID: 0029825160     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199652050-00007     Document Type: Review

References (167)

1. Silverstone T. Appetitie suppressants: a review. Drugs 1992 Jun; 43: 820-36
2. McTavish D, Heel RC. Dexfenfluramine: a review of its pharmacological properties and therapeutic potential in obesity. Drugs 1992 May; 43: 713-33
3. Blundell JE. Serotonin and appetite. Neuropharmacology 1984; 23: 1537-51
4. Blundell JE. Serotonin and the biology of feeding. Am J Clin Nutr 1992; 55: 1555-95
5. Noach EL. Appetite regulation by serotoninergic mechanisms and effects of d-fenfluramine. Neth J Med 1994 Sep; 45: 123-33
6. Turner P. Dexfenfluramine: its place in weight control. Drugs 1990 Jun; 39 Suppl. 3: 53-62
7. Caccia S, Anelli M, Fracasso C, et al. Anorectic effect and brain concentrations of D-fenfluramine in the marmoset: relationship to the in vivo and in vitro effects on serotonergic mechanisms. Naunyn Schmiedebergs Arch Pharmacol 1993 Mar; 347: 306-12
8. Gibson EL, Kennedy AJ, Curzon G. d-Fenfluramine- and d-norfenfluramine-induced hypophagia: differential mechanisms and involvement of postsynaptic 5-HT receptors. Eur J Pharmacol 1993 Sep 21; 242: 83-90
9. Garattini S, Mennini T, Bendotti C, et al. Neurochemical mechanism of action of drugs which modify feeding via the serotonergic system. Appetite 1986; 7 Suppl.: 15-38
10. Samanin R, Garattini S. Neurochemical mechanism of action of anorectic drugs. Pharmacol Toxicol 1993 Aug; 73: 63-8
11. 1B receptor mediates the effect of d-fenfluramine on eating caused by intra-hypothalamic injection of neuropeptide Y. Eur J Pharmacol 1995 Feb 14; 274: 221-4
12. Lawton CL, Blundell JE. 5-HT and carbohydrate suppression: effects of 5-HT antagonists on the action of d-fenfluramine and DOI. Pharmacol Biochem Behav 1993 Oct; 46: 349-60
13. Grignaschi G, Samanin R. Role of 5-HT receptors in the effect of d-fenfluramine on feeding patterns in the rat. Eur J Pharmacol 1992 Mar 3; 212: 287-9
14. 1B receptors. Nature 1992; 360: 161-3
15. Raiteri M, Bonanno G, Vallebuona F. In vitro and in vivo effects of d-fenfluramine: no apparent relation between 5-hydroxytryptamine release and hypophagia. J Pharmacol Exp Ther 1995 May; 273: 643-9
16. Oluyomi AO, Gibson EL, Barnfield AM, et al. d-Fenfluramine and d-norfenfluramine hypophagias do not require increased hypothalamic 5-hydroxytryptamine release. Eur J Pharmacol 1994 Oct 13; 264: 111-5
17. Chaouloff F. Effects of tianeptine on 5-HTP- and dextrofenfluramine-induced hypophagia in the rat. Pharmacol Biochem Behav 1993 Apr; 44: 989-92
18. Goodall EM, Cowen PJ, Franklin M, et al. Ritanserin attenuates anorectic, endocrine and thermic responses to d-fenfluramine in human volunteers. Psychopharmacology Berl 1993; 112: 461-6
19. Garattini S. An update on the pharmacology of serotoninergic appetite-suppressive drugs. Int J Obes 1992 Dec; 16 Suppl. 4: S41-8
20. Garattini S, Bizzi A, Caccia S, et al. Progress report on the anorectic effects of dexfenfluramine, fluoxetine and sertraline. Int J Obes 1992 Dec; 16 Suppl. 3: S43-50
21. Grignaschi G, Neill JC, Petrini A, et al. Feeding pattern studies suggest that d-fenfluramine and sertraline specifically enhance the state of satiety in rats. Eur J Pharmacol 1992 Feb 11; 211: 137-42
22. Blundell JE, Lawton CL. Serotonin and dietary fat intake: effects of dexfenfluramine. Metabolism 1995 Feb; 44: 33-7
23. Blundell JE, Hill AJ. Do serotonergic drugs decrease energy intake by reducing fat or carbohydrate intake? Effect of d-fenfluramine with supplemented weight-increasing diets. Pharmacol Biochem Behav 1988; 31: 773-8
24. Fisler JS, Underberger SJ, York DA, et al. d-Fenfluramine in a rat model of dietary fat-induced obesity. Pharmacol Biochem Behav 1993 Jun; 45: 487-93
25. Blundell JE, Hill AJ. Dexfenfluramine and appetite in humans. Int J Obes 1992 Dec; 16 Suppl. 3: 51-9
26. Wurtman JJ. Carbohydrate craving, mood changes, and obesity. J Clin Psychiatry 1988 Aug; 49 Suppl: 37-9
27. Wurtman JJ, Wurtman RJ. D-Fenfluramine selectively decreases carbohydrate but not protein intake in obese subjects. Int J Obes 1984; 8 Suppl. 1: 79-84
28. Wurtman J, Wurtman R, Berry E, et al. Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers. Neuropsychopharmacology 1993 Nov; 9: 201-10
29. Wurtman J, Wurtman R, Mark S, et al. d-Fenfluramine selectively suppresses carbohydrates snacking by obese subjects. Int J Eat Disord 1985; 4 (1): 89-99
30. Hill AJ, Blundell JE. Model system for investigating the actions of anorectic drugs: effect of d-fenfluramine on food intake, nutrient selection, food preferences, meal patterns, hunger and satiety in healthy human subjects. Adv Biosci 1986; 60: 377-89
31. Finer N. Drugs in focus: 6. Dexfenfluramine. Prescr J 1993; 33 (1): 16-21
32. Ricaurte GA, Molliver ME, Martello MB, et al. Dexfenfluramine neurotoxicity in brains of non-human primates [see comments]. Lancet 1991 Dec 14; 338: 1487-8
33. McCann U, Hatzidimitriou G, Ridenour A, et al. Dexfenfluramine and serotonin neurotoxicity: further preclinical evidence that clinical caution is indicated. J Pharmacol Exp Ther 1994 May; 269: 792-8
34. Campbell B, Dard-Brunelle B, Caccia S. The use of pharmacokinetics in the assessment of dexfenfluramine safety. Nicolaidis S. (Ed.) Proceedings of a symposium (Redux™ : a comprehensive overview) held on the occasion of the Benjamin Franklin Lafayette Seminar, La Napoule, 7 Jun 1996. In press.
35. Mennini T, Fracasso C, Cagnotto A, et al. In vitro and in vivo effects of the anorectic agent dexfenfluramine on the central serotonergic neuronal systems of non-human primates. A comparison with the rat. Naunyn Schmiedebergs Arch Pharmacol 1996; 353: 641-7
36. Caccia S, Sarati S, Anelli M, et al. Effect of escalating doses of d-fenfluramine on the content of indoles in brain. Neuropharmacology 1992 Sep; 31: 875-9
37. Bergami A, Fracasso C, Garattini S, et al. Brain uptake and acute indole-depleting effect of dexfenfluramine in squirrel monkeys after a high-dose regimen. Pharm Sci 1995 Jan; 1: 45-8
38. Bergami A, Fracasso C, Caccia S. The dexnorfenfluramine-to-dexfenfluramine plasma ratio in non-human primates [abstract]. Pharmacol Res 1995; 31 Suppl: 46
39. Caccia S, Bergami A, Fracasso C, et al. Oral kinetics of dexfenfluramine and dexnorfenfluramine in non-human primates. Xenobiotica 1995 Nov; 25: 1143-50
40. Rattray M, Wotherspoon G, Savery D, et al. Chronic D-fenfluramine decreases serotonin transporter messenger RNA expression in dorsal raphe nucleus. Eur J Pharmacol 1994 Aug 16; 268: 439-42
41. Kalia M, O'Malley NP. Brain serotonergic neurons demonstrate normal axonal transport following short- and long-term treatment with dexfenfluramine [abstract no. 437.6]. Soc Neurosci Abstr 1993; 19: 1060
42. Miller DB, O'Callaghan JP. The interactions of MK-801 with the amphetamine analogues d-methamphetamine (d-METH), 3,4-methylenedioxymethamphetamine (d-MDMA) or d-fenfluramine (d-FEN): neural damage and neural protection. Ann N Y Acad Sci 1993 May 28; 679: 321-4
43. Rose S, Hunt S, Collins P, et al. Repeated administration of escalating high doses of dexfenfluramine does not produce morphological evidence for neurotoxicity in the cortex of rats. Neurodegeneration 1996; 5: 145-52
44. 18F-altanserine positron emission tomography after dexfenfluramine treatment in obese subjects [abstract no. O406]. Int J Obes 1994 Aug; 18 Suppl. 2: 106
45. Voelker R. Obesity drug renews toxicity debate. JAMA 1994 Oct 12; 272: 1087-8
46. Baumgarten G, Garattini S, Lorens S, et al. Dexfenfluramine and neurotoxicity [letter]. Lancet 1992 Feb 8; 339: 359
47. Blundell JE. Dexfenfluramine and neurotoxicity [letter]. Lancet 1992 Feb 8; 339: 359-60
48. Guy-Grand B, Apfelbaum M, Crepaldi G, et al. Dexfenfluramine and neurotoxicity [letter]. Lancet 1992 Feb 8; 339: 360
49. Kalia M. Dexfenfluramine and neurotoxicity [letter]. Lancet 1992 Feb 8; 339: 360
50. Nicolaidis S. Dexfenfluramine and neurotoxicity [letter]. Lancet 1992 Feb 8; 339: 360
51. Bjorntorp P. Neuroendocrine abnormalities in human obesity. Metabolism 1995 Feb; 44 (2) Suppl. 2: 38-41
52. Felber J-P, Golay A. Regulation of nutrient metabolism and energy expenditure. Metabolism 1995 Feb; 44 (2) Suppl. 2: 4-9
53. Brindley DN. Neuroendocrine regulation and obesity. Int J Obes Relat Metab Disord 1992 Dec; 16 Suppl. 3: S73-9
54. Fontbonne A. Epidemiological data on hyperinsulinaemia and vascular disease. Diabetes Metab Rev 1993; 9 Suppl. 1: 13S-7S
55. Bouchard C. Dexfenfluramine and abdominal visceral fat. Obes Res 1996; 4 (1): 77-9
56. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607
57. Even P, Coulaud H, Nicolaïdis S. Lipostatic and ischymetric mechanisms originate dexfenfluramine-induced anorexia. Pharmacol Biochem Behav 1988 May; 30: 89-99
58. Levitsky DA, Stallone D. Enhancement of the thermic effect of food by d-fenfluramine. Clin Neuropharmacol 1988; 11 Suppl 1: S90-2
59. Rothwell NJ, Le Feuvre RA. Thermogenesis, brown adipose tissue and dexfenfluramine in animal studies. Int J Obes 1992 Dec; 16 Suppl. 3: 67-71
60. McCormack JG, Dean HG, Jennings GJ, et al. Effect of chronic low doses of d-fenfluramine on weight gain and calorie intake, brown adipose tissue thermogenic properties and brain neurotransmitter content in rats fed chow or palatable diets. Int J Obes 1989; 13: 625-33
61. Boschmann M, Frenz U, Noack R, et al. Energy metabolism and metabolite patterns of rats after application of dexfenfluramine. Int J Obes 1994 Apr; 18: 235-42
62. Boschmann M, Frenz U, Murphy CM, et al. Changes in energy metabolism and metabolite patterns of obese rats after application of dexfenfluramine. Pharmacol Biochem Behav 1996; 53 (3): 549-58
63. Brindley DN, Hales P, al-Sieni AI, et al. Sustained decreases in weight and serum insulin, glucose, triacylglycerol and cholesterol in JCR:LA-corpulent rats treated with D-fenfluramine. Br J Pharmacol 1992 Mar; 105: 679-85
64. Brindley DN, Russell JC. Metabolic abnormalities linked to obesity: effects of dexfenfluramine in the corpulent rat. Metabolism 1995 Feb; 44: 23-7
65. Schutz Y, Munger R, Dériaz O, et al. Effect of dexfenfluramine on energy expenditure in man. Int J Obes 1992 Dec; 16 Suppl. 3: 61-6
66. Scalfi L, D'Arrigo E, Carandente V, et al. The acute effect of dexfenfluramine on resting metabolic rate and postprandial thermogenesis in obese subjects: a double-blind placebo-controlled study. Int J Obes 1993 Feb; 17: 91-6
67. Recasens MA, Barenys M, Sola R, et al. Effect of dexfenfluramine on energy expenditure in obese patients on a very-low-calorie-diet. Int J Obes 1995 Mar; 19: 162-8
68. Kogon MM, Kräuchi K, Van der Velde P, et al. Psychological and metabolic effects of dietary carbohydrates and dexfenfluramine during a low-energy diet in obese women. Am J Clin Nutr 1994 Oct; 60: 488-93
69. Lafreniere F, Lambert J, Rasio E. Effects of dexfenfluramine treatment on body weight and postprandial thermogenesis in obese subjects. A double-blind placebo-controlled study. Int J Obes 1993 Jan; 17: 25-30
70. Van Gaal LF, Vansant GA, Steijaert MC, et al. Effects of dexfenfluramine on resting metabolic rate and thermogenesis in premenopausal obese women during therapeutic weight reduction. Metabolism 1995 Feb; 44 Suppl. 2: 42-5
71. Vanltallie TB. The role of dexfenfluramine in the regulation of energy balance. Introduction. Metabolism 1995 Feb; 44 Suppl. 2: 1-3
72. Anderson PH, Richelsen B, Bak J, et al. Influence of short-term dexfenfluramine therapy on glucose and lipid metabolism in obese non-diabetic patients. Acta Endocrinol 1993 Mar; 128: 251-8
73. Scheen AJ, Paolisso G, Salvatore T, et al. Improvement of insulin-induced glucose disposal in obese patients with NIDDM after 1-wk treatment with d-fenfluramine. Diabetes Care 1991 Apr; 14: 325-32
74. Proietto J, Thorburn AW, Fabris S. Effects of dexfenfluramine on glucose turnover in non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1994 Mar; 23: 127-34
75. Willey KA, Molyneaux LM, Yue DK. Obese patients with Type 2 diabetes poorly controlled by insulin and metformin: effects of adjunctive dexfenfluramine therapy on glycaemic control. Diabetic Med 1994 Aug-Sep; 11: 701-4
76. Marks SJ, Moore NR, Clark ML, et al. Reduction of visceral adipose tissue and improvement of metabolic indices: effect of dexfenfluramine in NIDDM. Obes Res 1996; 4 (1): 1-7
77. Kolanowski J, Younis LT, Vanbutsele R, et al. Effect of dexfenfluramine treatment on body weight, blood pressure and noradrenergic activity in obese hypertensive patients. Eur J Clin Pharmacol 1992 Jun; 42: 599-606
78. Andersson B, Zimmermann ME, Hedner T, et al. Haemodynamic, metabolic and endocrine effects of short-term dexfenfluramine treatment in young, obese women. Eur J Clin Pharmacol 1991; 40: 249-54
79. Ditschuneit HH, Flechtner-Mors M, Dolderer M, et al. Endocrine and metabolic effects of dexfenfluramine in patients with android obesity. Horm Metab Res 1993 Nov; 25: 573-8
80. Greco AV, Mingrone G, Capristo E, et al. Effects of dexfenfluramine on free fatty acid turnover and oxidation in obese patients with type 2 diabetes mellitus. Metabolism 1995 Feb; 44: 57-61
81. Greco AV, Mingrone G, Tataranni PA, et al. Turnover and oxidation rates of plasma-free fatty acids in obese patients treated with dexfenfluramine. Ann Nutr Metab 1993 Sep-Oct; 37: 237-44
82. Kars ME, Pijl H, Cohen AF, et al. Specific stimulation of brain serotonin mediated neurotransmission by dexfenfluramine does not restore growth hormone responsiveness in obese women. Clin Endocrinol 1996; 44: 541-6
83. Drent ML, Adèr HJ, van der Veen EA. The influence of chronic administration of the serotonin agonist dexfenfluramine on responsiveness to corticotropin releasing hormone and growth hormone-releasing hormone in moderately obese people. J Endocrinol Invest 1995 Nov; 18: 780-8
84. Bernini GP, Argenio GF, Del Corso C, et al. Serotoninergic receptor activation by dextrofenfluramine enhances the blunted pituitary-adrenal responsiveness to corticotropin-releasing hormone in obese subjects. Metabolism 1992 Jan; 41: 17-21
85. Horowitz M, Maddox A, Wishart J, et al. Effect of dexfenfluramine on gastric emptying of a mixed solid-liquid meal in obese subjects. Br J Nutr 1990 May; 63: 447-55
86. Caccia S, Ballabio M, Guiso G, et al. Species differences in the kinetics and metabolism of fenfluramine isomers. Arch Int Pharmacodyn Ther 1982 Jul; 258: 15-28
87. Cheymol G, Weissenburger J, Poirier JM, et al. The pharmacokinetics of dexfenfluramine in obese and non-obese subjects. Br J Clin Pharmacol 1995 Jun; 39: 684-7
88. Gross AS, Phillips AC, Rieutord A, et al. The influence of the sparteine/debrisoquine genetic polymorphism on the disposition of dexfenfluramine. Br J Clin Pharmacol 1996; 41: 311-7
89. Marchant NC, Breen MA, Wallace D, et al. Comparative biodisposition and metabolism of 14C-(+/-)-fenfluramine in mouse, rat, dog and man. Xenobiotica 1992 Nov; 22: 1251-66
90. Marbury TC, Angelo JE, Gulley MR, et al. A placebo-controlled dose-response study of dexfenfluramine in the treatment of obesity. Curr Ther Res. In press
91. Caccia S, Conforti I, Duchier J, et al. Pharmacokinetics of fenfluramine and norfenfluramine in volunteers given d- and dl-fenfluramine for 15 days. Eur J Clin Pharmacol 1985; 29: 221-4
92. Jain A, Vargas R, Cary M, et al. Pharmacokinetics of dexfenfluramine in obese and non-obese subjects [abstract]. 95th Annu Meet Am Soc Clin Pharmacol Ther 1994: 142
93. Guy-Grand B, Crepaldi G, Lefebvre P, et al. International trial of long-term dexfenfluramine in obesity. Lancet 1989 Nov 11; 2: 1142-4
94. Metropolitan Life Insurance Company. 1983 Metropolitan height and weight tables. Stat Bull Metropol Life Insur Co 1984; 64: 2-9
95. Lorentz FM. Ein neuer konstitutionsindex. Klin Wochenschr 1929; 8: 348-51
96. VanItallie TB. Worldwide epidemiology of obesity. PharmacoEconomics 1994; 5 Suppl. 1: 1-7
97. Schoeller DA. Limitations in the assessment of dietary energy intake by self-report. Metabolism 1995 Feb; 44 (2) Suppl. 2: 18-22
98. Black AE, Prentice AM, Golding GR, et al. Measurements of total energy expenditure provide insights into the validity of dietary measurements of energy intake. J Am Diet Assoc 1993; 93: 572-9
99. Drent ML, Zelissen PMJ, Koppeschaar HPF, et al. The effect of dexfenfluramine on eating habits in a Dutch ambulatory android overweight population with an overconsumption of snacks. Int J Obes 1995 May; 19: 299-304
100. Holdaway IM, Wallace E, Westbrooke L, et al. Effect of dexfenfluramine on body weight, blood pressure, insulin resistance and serum cholesterol in obese individuals. Int J Obes 1995 Oct; 19: 749-51
101. Lucas CP, Sandage BW. Treatment of obese patients with dexfenfluramine: a multicenter, placebo-controlled study. Amer J Therap 1995; 2: 962-7
102. Stewart GO, Stein GR, Davis TME. Dexfenfluramine in type II diabetes: effect on weight and diabetes control. Med J Aust 1993 Feb 1; 158: 167-9
103. Willey KA, Molyneaux LM, Overland JE, et al. The effects of dexfenfluramine on blood glucose control in patients with Type 2 diabetes. Diabetic Med 1992 May; 9: 341-3
104. Bremer JM, Scott RS, Lintott CJ. Dexfenfluramine reduces cardiovascular risk factors. Int J Obes 1994 Apr; 18: 199-205
105. Breum L, Pedersen JK, Ahlstrhm F, et al. Comparison of an ephedrine/caffeine combination and dexfenfluramine in the treatment of obesity. A double-blind multi-centre trial in general practice. Int J Obes Relat Metab Disord 1994 Feb; 18: 99-103
106. Drouin P, Hanotin C, Thomas F, et al. Efficacy and tolerability of sibutramine versus dexfenfluramine in obese patients [abstract]. European Congress on Obesity. 1995
107. Hosker JP, Matthews DR, Rudenski AS, et al. Continuous infusion of glucose with model assessment: measurement of insulin resistance and β-cell function in main. Diabetologia 1985; 28: 401-11
108. Sandage Jr. B, Loar S, Laudignon N. Review of dexfenfluramine efficacy and tolerability [abstract no. P511]. Int J Obes 1994; 18 Suppl. 2 109. Manning RM, Jung RT, Leese GP, et al. The comparison of four weight reduction strategies aimed at overweight diabetic patients. Diabetic Med 1995 May; 12: 409-15
109. Sandage Jr. B, Loar S, Laudignon N. Review of dexfenfluramine efficacy and tolerability [abstract no. P511]. Int J Obes 1994; 18 Suppl. 2 109. Manning RM, Jung RT, Leese GP, et al. The comparison of four weight reduction strategies aimed at overweight diabetic patients. Diabetic Med 1995 May; 12: 409-15
110. Sandage Jr. BW, Loar SB, Cary M, et al. Predictors of therapeutic success with dexfenfluramine [abstract no. O122]. Obes Res 1995; 3 Suppl. 3: 355S
111. Guy-Grand B, Apfelbaum M, Crepaldi G, et al. Short-term predictors of successful weight loss with dexfenfluramine (dF) [abstract no. 08-175-WA1]. Int J Obes 1996; 20 Suppl. 4: 70
112. Guy-Grand B, Apfelbaum M, Crepaldi G, et al. Dexfenfluramine (dF) lowers blood pressure independently of weight loss: data from the INDEX study (abstract no. O404]. Int J Obes 1994; 18 Suppl. 2: 106
113. Breum L, Mhller S-E, Andersen T, et al. Long-term effect of dexfenfluramine on amino acid profiles and food selection in obese patients during weight loss. Int J Obes 1996; 20: 147-53
114. Noble RE. A six-month study ot the effects of dexfenfluramine on partially successful dieters. Curr Ther Res 1990; 47 (4): 612-9
115. Finer N. Body weight evolution during dexfenfluramine treatment after initial weight control. Int J Obes 1992 Dec; 16 Suppl. 3: S25-9
116. Finer N, Finer S, Naoumova RP. Drug therapy after very-low-calorie diets. Am J Clin Nutr 1992 Jul; 56 (1 Suppl): 195S-8S
117. Mathus-Vliegen EMH, Van de Voorde K, Kok AME, et al. Dexfenfluramine in the treatment of severe obesity: a placebo-controlled investigation of the effects on weight loss, cardiovascular risk factors, food intake and eating behaviour. J Intern Med 1992 Aug; 232: 119-27
118. O'Connor HT, Richman RM, Steinbeck KS, et al. Dexfenfluramine treatment of obesity: a double blind trial with post trial follow up. Int J Obes 1995 Mar; 19: 181-9
119. Guy-Grand B, Apfelbaum M, Crepaldi G, et al. Effect of withdrawal of dexfenfluramine on body weight and food intake after a one year's administration [abstract no. IF-4]. Int J Obes 1990; 14 Suppl. 2: 48
120. Pfohl M, Luft D, Blomberg I, et al. Long-term changes of body weight and cardiovascular risk factors after weight reduction with group therapy and dexfenfluramine. Int J Obes 1994 Jun; 18: 391-5
121. Ditschuneit HH, Flechtner-Mors M, Adler G. The effect of withdrawal and re-introduction of dexfenfluramine in the treatment of obesity. Int J Obes 1996 Mar; 20: 280-2
122. Enzi G, DIMOS Group. Dexfenfluramine Italian Multicentre Open Study (DIMOS): efficacy and safety of dexfenfluramine in the treatment of patients with simple or complicated obesity. Clin Drug Invest 1995 Nov; 10: 249-56
123. Atanassoff PG, Weiss BM, Schmid ER, et al. Pulmonary hypertension and dexfenfluramine [letter]. Lancet 1992 Feb 15; 339: 436
124. Roche N, Labrune S, Braun J-M. Pulmonary hypertension and dexfenfluramine [letter]. Lancet 1992 Feb 15; 339: 436-7
125. Primary pulmonary hypertension on appetite suppressants. Presc Int 1995 Dec; 4: 180-1
126. Fenfluramine (Ponderax pacaps), dexfenfluramine (Adifax) and pulmonary hypertension. Curr Prob 1992 Jun; 34: 1-2
127. Pouwels HM, Smeets JL, Cheriex EC, et al. Pulmonary hypertension and fenfluramine. Eur Respir J 1990 May; 3: 606-7
128. Fotiadis I, Apostolou T, Koukoulas A, et al. Fenfluramine-induced irreversible pulmonary hypertension [letter]. Postgrad Med J 1991 Aug; 67: 776-7
129. Ferrari E, Drai E, Jourdan J, et al. Severe pulmonary hypertension complicating long-term dexfenfluramine treatment [in French]. Arch Mal Coeur Vaiss 1994 Feb; 87: 285-6
130. Brenot F, Herve P, Petitpretz P, et al. Primary pulmonary hypertension and fenfluramine use [see comments]. Br Heart J 1993 Dec; 70: 537-41
131. Cacoub P, Dorent R, Nataf P, et al. Pulmonary hypertension and dexfenfluramine. Eur J Clin Pharmacol 1995; 48 (1): 81-3
132. Douglas JG, Munro JF, Kitchin AH, et al. Pulmonary hypertension and fenfluramine. Br Med J Clin Res Ed 1981 Oct 3; 283: 881-3
133. Gaul G, Blazek G, Deutsch E, et al. A case of chronic pulmonary hypertension after fenfluramine intake [in German]. Wien Klin Wochenschr 1982 Nov 26; 94: 618-22
134. The International Primary Pulmonary Hypertension Study Group. The International Primary Pulmonary Hypertension Study (IPPHS). Chest 1994; 105 (2) Suppl.: 37S-41S
135. Abenhaim L. Pharmacoepidemiology of primary pulmonary hypertension [abstract no. 190]. Pharmacoepidemiol Drug Saf 1995 Aug; 4 Suppl. 1: S86
136. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppresent drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996 Aug 29; 335 (9): 609-16
137. Manson JE, Faich GA. Pharmacotherapy for obesity - do the benefits outweigh the risks? [editorial]. N Engl J Med 1996 Aug 29; 335 (9): 659-60
138. Servier International. Dexfenfluramine prescribing information. Europe, 1996
139. Committee for Proprietary Medicinal Products. Opinion on anorectics dexfenfluramine and fenfluramine. 1996 Jul 17; London
140. Wyeth-Ayerst. Dexfenfluramine prescribing information. US, 1996.
141. Laurier D, Guiguet M, Chau NP, et al. Prevalence of obesity: a comparative study in France, the United Kingdom and the United States. Int J Obes 1992; 16: 565-72
142. Kuczmarski RJ, Flegal KM, Campbell SM, et al. Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA 1994 Jul 20; 272 (3): 205-11
143. Wolf AM, Colditz GA. The cost of obesity: the US perspective. PharmacoEconomics 1994; 5 Suppl. 1: 34-7
144. Segal L, Carter R, Zimmet P. The cost of obesity. The Australian perspective. PharmacoEconomics 1994; 5 Suppl. 1: 45-52
145. Seidell JC, Deerenberg I. Obesity in Europe. Prevalence and consequences for use of medical care. PharmacoEconomics 1994; 5 Suppl. 1: 38-44
146. Sorensen TJA, Price RA, Stunkard A, et al. Genetics of obesity in adult adoptees and their biological siblings. BMJ 1989; 298: 87-90
147. Stunkard AJ, Sorensen TJA, Hanis C, et al. An adoption study of human obesity. N Engl J Med 1986; 314: 193-8
148. Stunkard AJ, Harris JR, Rederson NL, et al. The body mass index of twins who have been reared apart. N Engl J Med 1990; 322: 1483-7
149. Savard R, Bouchard C, Leblanc C, et al. Familial resemblance in fatness indicators. Ann Hum Biol 1983; 2: 111-8
150. Blundell JE, Halford JCG. Pharmacological aspects of obesity treatment: towards the 21st century. Int J Obes 1995 Sep; 19 Suppl. 3: 51-5
151. Caterson ID. Management strategies for weight control. Eating, exercise and behaviour. Drugs 1990 Jun; 39 Suppl. 3: 20-32
152. Safer DJ. Diet, behavior modification, and exercise: a review of obesity treatments from a long-term perspective. South Med J 1991 Dec; 84: 1470-4
153. Atkinson RL, Hubbard VS. Report on the NIH workshop on pharmacologic treatment of obesity. Am J Clin Nutr 1994 Aug; 60: 153-6
154. Bray GA. Use and abuse of appetite-suppressant drugs in the treatment of obesity. Ann Intern Med 1993 Oct 1; 119 Suppl. 7 Pt 2: 707-13
155. Pi-Sunyer X. Guidelines for the approval and use of drugs to treat obesity - a position paper of the North American Association for the Study of Obesity. Obes Res 1995 Sep; 3: 473-8
156. Enzi G. Socioeconomic consequences of obesity. The effect of obesity on the individual. PharmacoEconomics 1994; 5 Suppl. 1: 54-7
157. Blackburn GL. Comparison of medically supervised and unsupervised approaches to weight loss and control. Ann Intern Med 1993; 119: 714-8
158. Stunkard AJ. Current views on obesity. Am J Med 1996; 100: 230-6
159. Pi-Sunyer X. The NAASO position paper on approval and use of drugs to treat obesity. Obes Res 1995 Sep; 3: 471-2
160. Atkinson RL, Dietz WH, Foreyt JP, et al. Very low-calorie diets. JAMA 1993 Aug 25; 270: 967-74
161. Garrow JS. Drugs for the treatment of obesity: what do we need? Pharm Med 1990; 4: 213-8
162. Beales PL, Kopelman PG. Options for the management of obesity. PharmacoEconomics 1994; 5 Suppl. 1: 18-32
163. Hutton J. The economics of treating obesity. PharmacoEconomics 1994; 5 Suppl. 1: 66-72
164. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins:a meta-analysis. Am J Clin Nutr 1992 Aug; 56: 320-8
165. Goldstein DJ, Potvin JH. Long-term weight loss: the effect of pharmacologic agents. Am J Clin Nutr 1994 Nov; 60: 647-57
166. Lean MEJ, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. BMJ 1995; 311: 158-61
167. Han TS, van Leer EM, Seidell JC, et al. Waist circumference action level in the identification of cardiovascular risk factors: prevalence study in a random sample. BMJ 1995; 311: 1401-5